High quality LY 341495 and Amyloid beta (1-42) available in Ascent Scientific's new Low-Cost Ligand catalogue - at affordable prices
September 03, 2009 (PRLEAP.COM) Health NewsAscent Scientific (www.ascentscientific.com) announced the launch of the new Low-Cost Ligand™ 2009 catalogue. New products include LY 341495 (an mGlu Group II antagonist), Amyloid beta (1-42) (a peptide important for Alzheimer's research), UCPH-101 (a novel selective EAAT1 blocker) and many more.
The expanded ranges include glutamate, cannabinoids, GABA, ion channels, and signalling.
Steve Roome, Commercial Director announced, "Thanks to feedback from our customers, we have added some very exciting products to our new Autumn 2009 catalogue. These products include the potent selective group II glutamate antagonist, LY 341495 and a novel glutamate uptake blocker, selective for EAAT1.
In addition to our glutamate range, we have expanded other product areas, such as apoptosis and cellular signalling – new products include Amyloid beta (1-42) (human) and a variety of kinase inhibitors.
Our team has worked hard to offer these new products at affordable prices (many are at half the price of other suppliers) – whilst still retaining Ascent Scientific's reputation for extremely high quality, purity and accuracy."
Contact: Steve Roome, Commercial Director +44 (0)117 982 99 88
About Ascent Scientific
Ascent Scientific offers a range of high quality receptor ligands and synthetic chemistry services at prices so low that as many researchers as possible will be able to afford them.
The Low-Cost Ligand range includes receptor ligands and signalling tools in research areas such as glutamate, GABA, ion channels, cannabinoids, opioids, 5-HT and more.
The Low-Cost Chemistry Service provides cost-effective custom synthesis of organic molecules, fluorescent labels, standards & references, stable isotope labels, receptor ligands and more.
To request a new catalogue, visit our website www.ascentscientific.com, or contact customer service at firstname.lastname@example.org.